<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028364</url>
  </required_header>
  <id_info>
    <org_study_id>IJB-BCTL:20120306</org_study_id>
    <secondary_id>2012-004860-22</secondary_id>
    <nct_id>NCT02028364</nct_id>
  </id_info>
  <brief_title>Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Pet Imaging as a Biomarker of Everolimus Added Value in Hormone Refractory postmenopausaL Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm trial in which patients with locally advanced or metastatic&#xD;
      endocrine receptor positive and HER2 negative breast cancer refractory to non-steroidal&#xD;
      aromatase inhibitors (NSAI) will receive Everolimus 10mg orally daily given in conjunction&#xD;
      with exemestane 25mg orally daily until disease progression or treatment discontinuation for&#xD;
      any other reasons. The main objectives are to evaluate if early metabolic response (MR) using&#xD;
      FDG-PET/CT is associated with progression free survival (PFS) and overall survival (OS) in&#xD;
      this population.&#xD;
&#xD;
      Tumour, metastatic lesions and blood samples will be collected during the treatment period in&#xD;
      order to identify biomarkers predicting resistance to study treatment. Results will be&#xD;
      correlated with the results of early FDG PET/CT data in order to better characterise the&#xD;
      non-responders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS based on RECIST criteria 1.1.</measure>
    <time_frame>2.5 years from FPI</time_frame>
    <description>To evaluate if early metabolic response (MR) using FDG-PET/CT is associated with progression free survival (PFS) in ER+, HER2 negative ABC or MBC patients treated with exemestane plus everolimus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2.5 years from first patient in</time_frame>
    <description>To evaluate if early metabolic response (MR) using FDG-PET/CT is associated with overall survival (OS) in ER+, HER2 negative locally advanced or MBC patients treated with exemestane plus everolimus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>* Proportion of FDG-PET/CT metabolic non-responders/FDG-PET/CT metabolic responders * Estimate the most suitable second FDG-PET/CT time point (2 weeks versus 4 weeks after initiation of treatment).</measure>
    <time_frame>Baseline, day 14, Day 28 and at progression</time_frame>
    <description>FDG PET/CT will be done three times during the pilot phase of the study (first 30 patients): at baseline (at day 0, Day 14 and day 28). FDG PET/CT will be done twice during the extension phase: at baseline (at day 0, Day 14 or Day 28) depending the results of the pilot phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assessment</measure>
    <time_frame>baseline, day 14, day 28, every 12 weeks and at progression</time_frame>
    <description>The aim is to identify biomarkers predicting resistance to exemestane and everolimus therapy by studying primary tumor, metastatic biopsies and serial plasma samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus given in conjunction with exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10mg orally daily</description>
    <arm_group_label>Everolimus given in conjunction with exemestane</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>25mg orally daily</description>
    <arm_group_label>Everolimus given in conjunction with exemestane</arm_group_label>
    <other_name>Aromasin, Exemestane Teva, Exemestane Sandoz, Exemarom,Exemestane Mylan, Exemestane Accord Healthcare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult women (≥18 years of age) with locally advanced or metastatic breast cancer not&#xD;
             amenable to curative treatment by surgery or radiotherapy.&#xD;
&#xD;
          2. Histological or cytological confirmation of estrogen-receptor positive (ER+), HER2&#xD;
             negative breast cancer.&#xD;
&#xD;
          3. Postmenopausal female defined as:&#xD;
&#xD;
               -  Age ≥55 years and one year or more of amenorrhoea&#xD;
&#xD;
               -  Age &lt;55 years and one year or more of amenorrhoea, with an estradiol assay&#xD;
                  &lt;20pg/ml&#xD;
&#xD;
               -  Surgical menopause with bilateral oophorectomy NOTE: Ovarian radiation or&#xD;
                  treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (goserelin&#xD;
                  or leuprolide) is not permitted for induction of ovarian suppression.&#xD;
&#xD;
          4. Breast cancer that is refractory to non-steroidal aromatase inhibitors (NSAI) (i.e.&#xD;
             anastrozole or letrozole) defined as:&#xD;
&#xD;
               -  Recurrence while on, or within 12 months of end of adjuvant treatment with&#xD;
                  anastrozole or letrozole; OR&#xD;
&#xD;
               -  Progression while on, or within one month of end of anastrozole or letrozole or&#xD;
                  treatment for locally advanced or metastatic breast cancer.&#xD;
&#xD;
             NOTE: Letrozole or anastrozole do not have to be the last treatment prior to&#xD;
             enrolment.&#xD;
&#xD;
          5. FDG-PET measurable disease defined as: at least one target lesion fulfilling following&#xD;
             criteria:&#xD;
&#xD;
               -  Size ≥1.5cm; AND&#xD;
&#xD;
               -  FDG-PET avid lesion with uptake above the background liver uptake as described&#xD;
                  below: i.e. with a marked accumulation of FDG, at least 1.5-fold greater than&#xD;
                  liver SUV mean + 2 SDs (in 3cm spherical ROI in normal right lobe of liver). If&#xD;
                  liver is abnormal, target lesion should have uptake &gt; 2.0 x SUV mean of blood&#xD;
                  pool in 1cm diameter ROI in descending thoracic aorta)&#xD;
&#xD;
             NB:&#xD;
&#xD;
               -  The target lesion can be a bone metastasis if it fulfils the above mentioned&#xD;
                  criteria.&#xD;
&#xD;
               -  In the case the target lesion is a lymph node, the small axis should be ≥ 1.5cm.&#xD;
&#xD;
          6. Radiological or clinical evidence of recurrence or progression on last systemic&#xD;
             therapy prior to enrolment.&#xD;
&#xD;
          7. Adequate bone marrow function as shown by:&#xD;
&#xD;
               -  Haemoglobin (HgB) ≥9.0 g/dL&#xD;
&#xD;
               -  ANC ≥1,500/mm3 (≥1.5 x 109/L)&#xD;
&#xD;
               -  Platelets ≥100,000/mm3 (≥100x 109/L)&#xD;
&#xD;
          8. Adequate liver function as shown by:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5xULN (or&#xD;
                  ≤5 if hepatic metastases are present)&#xD;
&#xD;
               -  Total serum bilirubin ≤1.5 x ULN (≤3 ULN for patients known to have Gilbert&#xD;
                  Syndrome)&#xD;
&#xD;
          9. Adequate renal function as shown by Serum creatinine ≤1.5 x ULN&#xD;
&#xD;
         10. Fasting serum cholesterol, triglycerides and glucose&#xD;
&#xD;
               -  Fasting serum cholesterol ≤300 mg/dL or 7.75 mmol/L&#xD;
&#xD;
               -  Fasting triglycerides ≤2.5 x ULN&#xD;
&#xD;
               -  Fasting glucose &lt; 1.5 x ULN&#xD;
&#xD;
         11. Eastern Co-operative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
         12. Written and signed informed consent obtained before any trial related activity.&#xD;
&#xD;
         13. Availability of a FFPE core of primary breast tumor&#xD;
&#xD;
         14. Possibility to obtain the mandatory blood samples for the translational research&#xD;
             studies.&#xD;
&#xD;
         15. For patients with accessible metastatic lesions, possibility to obtain the mandatory&#xD;
             biopsy (FFPE and frozen) of a metastatic lesion&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ&#xD;
             hybridization positive).&#xD;
&#xD;
          2. Patients with only non-measurable lesions by FDG-PET/CT (e.g. pleural effusion,&#xD;
             ascites etc.).&#xD;
&#xD;
          3. Symptomatic visceral disease for example liver, pulmonary metastases or lymphangitis&#xD;
             carcinomatosis.&#xD;
&#xD;
          4. Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).&#xD;
&#xD;
          5. Another malignancy within 5 years prior to enrolment, with the exception of adequately&#xD;
             treated in-situ carcinoma of the cervix, uteri, basal or squamous cell carcinoma or&#xD;
             non-melanomatous skin cancer.&#xD;
&#xD;
          6. Radiotherapy within four weeks prior to enrolment except in case of localized&#xD;
             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can&#xD;
             then be completed within two weeks prior to enrolment. Patients must have recovered&#xD;
             from radiotherapy toxicities prior to enrolment.&#xD;
&#xD;
          7. Currently receiving hormone replacement therapy, unless discontinued prior to&#xD;
             enrolment.&#xD;
&#xD;
          8. Symptomatic brain metastases or other central nervous system metastases which are not&#xD;
             controlled by local treatments.&#xD;
&#xD;
          9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroid use&#xD;
             at the time of study entry except in cases outlined below:&#xD;
&#xD;
               -  Topical applications (e.g. rash)&#xD;
&#xD;
               -  Inhaled sprays (e.g. obstructive airways disease)&#xD;
&#xD;
               -  Eye drops&#xD;
&#xD;
               -  Local injections (e.g. intra-articular)&#xD;
&#xD;
               -  Stable low dose of corticosteroids for at least two weeks before enrolment&#xD;
&#xD;
         10. Patients with known HIV seropositivity. Screening for HIV infection at baseline is not&#xD;
             required&#xD;
&#xD;
         11. Acute and chronic, active infectious disorders (except for Hepatitis B and Hepatitis C&#xD;
             positive patients).&#xD;
&#xD;
         12. Active bleeding diathesis, or on oral anti-vitamin K medication (except low dose&#xD;
             warfarin, LMWH and acetylsalicylic acid or equivalent, as long as the INR is ≤ 2.0).&#xD;
&#xD;
         13. Any severe uncontrolled medical conditions such as:&#xD;
&#xD;
               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction ≤6 months prior to enrolment, uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Uncontrolled diabetes as defined by fasting glucose ≥ 1.5 x ULN&#xD;
&#xD;
               -  Acute and chronic, active infectious disorders and non-malignant medical&#xD;
                  illnesses that are uncontrolled or whose control may be jeopardized by the&#xD;
                  complications of this study therapy.&#xD;
&#xD;
               -  Symptomatic deterioration of lung function&#xD;
&#xD;
         14. Patients being treated with drugs recognized as being strong inhibitors or inducers of&#xD;
             the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole,&#xD;
             Itraconazoleonazole, Voriconazole, Ritonavir, Telithromycin) within the last 5 days&#xD;
             prior to enrolment.&#xD;
&#xD;
         15. History of non-compliance to medical regimens.&#xD;
&#xD;
         16. Patients unwilling or unable to comply with the protocol.&#xD;
&#xD;
         17. Concurrent anti-cancer treatment in another investigational trial, including hormonal&#xD;
             therapy, immunotherapy or targeted agents other than those administered in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Gombos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insitut Jules Bordet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Flamen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universtaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternité Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced breast cancer</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>NSAI refractory</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Estrogen-receptor positive (ER+)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

